What Are Bacterial Extracellular Vesicles?

Bacterial extracellular vesicles (BEVs) are tiny membrane-bound bubbles, typically between 20 and 400 nanometers across, that bacteria release into their surroundings. They carry a concentrated payload of proteins, lipids, DNA, RNA, and signaling molecules, functioning as a long-range delivery system that lets bacteria influence other cells without direct contact. Once dismissed as cellular debris, these vesicles are now recognized as a universal feature of bacterial life, produced by species across every major bacterial group and playing roles in everything from antibiotic resistance to ocean ecology.

How Bacteria Build and Release Vesicles

The best-understood type of BEV comes from gram-negative bacteria, the group that includes organisms like E. coli and Salmonella. These bacteria have a double-membrane cell envelope, and their outer membrane vesicles (OMVs) form when small portions of the outer membrane bulge outward and pinch off, a process sometimes described as “blebbing.”¹ The resulting spherical particles are naturally loaded with whatever molecules were present in that patch of outer membrane and the space beneath it, including surface proteins, toxins, and fragments of genetic material.²

For a long time, researchers assumed gram-positive bacteria couldn’t produce vesicles at all. These species have only a single cell membrane, surrounded by a thick, rigid cell wall that seemed like it would physically block any blebbing. But studies over the past decade have upended that assumption. Gram-positive species, including common pathogens like Staphylococcus aureus and Streptococcus pneumoniae, do release vesicles. The mechanism appears to involve remodeling of the cell wall itself to allow the membrane bubbles to escape, and it may be more similar to the gram-negative process than the vastly different cell-wall architectures would suggest.³ Vesicle production has also been documented in archaea and mycobacteria, which means this is not a niche trick of a few species. It appears to be a conserved behavior across all three domains of life.⁴

What Goes Inside a Vesicle

BEVs are not just random scraps of membrane. Their contents are selectively sorted during formation. Cargo loading is driven by electrostatic interactions between molecules and the membrane, by interactions with lipoproteins embedded in the membrane, and by proteins that recognize and are drawn to the curved surfaces forming during the blebbing process.⁵ The result is a vesicle whose molecular profile often differs from the parent cell’s overall composition, enriched in certain proteins or nucleic acids that serve specific functions once delivered.

A typical vesicle’s cargo list reads like a microbial toolkit. It can include membrane proteins, enzymes, toxins, genomic DNA, plasmids, short RNA molecules, signaling molecules used for quorum sensing (the chemical “language” bacteria use to coordinate group behavior), and various lipids including lipopolysaccharide (LPS), the molecule on gram-negative cell surfaces that strongly activates the human immune system.⁶ This diversity means a single vesicle can simultaneously deliver a chemical signal, a chunk of DNA, and an immune-stimulating molecule to a distant target.

A Weapon and a Shield

One of the most consequential roles BEVs play is in bacterial defense. Vesicles can soak up antimicrobial peptides, the natural antibiotic-like molecules produced by human immune cells and other organisms, reducing their effectiveness against the bacteria that released the vesicles. They also carry and transfer antibiotic resistance genes, store efflux pumps (proteins that actively pump drugs out of cells), and can even serve as decoys that bind bacteriophages, the viruses that attack bacteria.⁷ In effect, bacteria can create a cloud of protective vesicles around themselves, neutralizing chemical threats and viral attackers before they reach the cell surface.

The ability of BEVs to spread antibiotic resistance genes is particularly worrying from a public health standpoint. This is a form of horizontal gene transfer, where genetic material passes between bacteria without reproduction. In Vibrio cholerae, the bacterium responsible for cholera, stress-induced vesicles have been shown to promote the transfer of chromosomal antibiotic resistance genes both in the lab and during intestinal colonization.⁸ The same process has been observed in gram-positive bacteria: vesicles from Streptococcus pneumoniae carry bacterial DNA on their surface and can deliver it to other pneumococcal cells, potentially spreading drug resistance genes through the population.⁹ This vesicle-mediated gene sharing may be an underappreciated driver of the antibiotic resistance crisis.

Delivering Toxins and Crossing the Blood-Brain Barrier

From the perspective of infection, BEVs give pathogenic bacteria a way to project force at a distance. Vesicles loaded with toxins and other virulence factors can travel through body fluids to reach host cells far from the site of the bacterial colony itself. This has sometimes been called “secretion system type zero,” a nod to the numbered secretion systems that bacteria use for direct injection of molecules into host cells. Unlike those systems, which require close contact, vesicle-mediated delivery works over long distances and can target cell types the bacteria never physically touch.¹⁰

Perhaps the most striking example of this long-range capability is the ability of BEVs to cross the blood-brain barrier. Researchers have documented vesicles from intestinal and oral bacteria carrying protein toxins into the central nervous system, a finding that has prompted investigation into whether BEVs play a role in neurological conditions linked to chronic infection or gut dysbiosis.¹⁰ The idea that bacteria in your gut could send molecular packages to your brain, without any bacterium leaving the intestine, is one of the reasons BEVs have attracted so much research attention in recent years.

How Your Immune System Responds

Because BEVs carry bacterial surface molecules, they activate the immune system in many of the same ways that whole bacteria do. Human cells detect vesicles through pattern-recognition receptors, including the toll-like receptors (TLRs) that evolved to sense microbial components. A human enzyme called secretory phospholipase A2-IIA (sPLA2-IIA) appears to play a modulatory role in this process, physically altering bacterial vesicles in ways that change how strongly they activate immune signaling through TLR pathways.¹¹ This suggests the human body has evolved specific tools to interact with, and control its response to, bacterial vesicles.

The immune activation caused by BEVs is a double-edged sword. In infections, vesicle-triggered inflammation contributes to tissue damage. But in the context of the healthy gut microbiome, vesicles from commensal bacteria help train and calibrate the immune system, keeping it alert without overreacting.

Gut Health and the Microbiome

Not all BEVs are harmful. The trillions of bacteria that make up the gut microbiome continuously release vesicles that play a constructive role in intestinal health. These vesicles interact with gut lining cells and the local immune system, influencing microbial ecosystems and helping preserve the intestinal barrier. Vesicles from the probiotic strain Escherichia coli Nissle 1917, for instance, attach to receptors on gut epithelial cells and trigger signaling pathways that increase the production and redistribution of tight junction proteins, the molecular “rivets” that hold the gut lining together. One of these, Claudin-14, is associated with decreased intestinal permeability, meaning the barrier becomes less leaky and better at keeping harmful substances from crossing into the bloodstream.¹²

More broadly, microbiota-derived vesicles are now understood as key players in the cross-talk between gut bacteria and the human body, controlling aspects of host metabolism, barrier integrity, and immune training.¹³ The composition of vesicles in the gut shifts when the microbiome is disrupted, and researchers are investigating whether these shifts could serve as early indicators of conditions like inflammatory bowel disease.

BEVs Already in Vaccines

The most mature medical application of BEVs is in vaccines, and it has been in use for decades. Outer membrane vesicle vaccines against meningococcal group B disease have been deployed widely in Cuba, New Zealand, and Brazil, offering good protection against the targeted strains in older children and adults. The effectiveness of these vaccines turned out to be broader than expected, working against a wider range of meningococcal strains than initial lab tests predicted. More recently, researchers discovered that meningococcal OMV vaccines may also provide some protection against Neisseria gonorrhoeae, the closely related bacterium that causes gonorrhea, a finding with major implications given the lack of any licensed gonorrhea vaccine.¹⁴ Two OMV-containing group B meningococcal vaccines are currently available globally.¹⁵

The reason BEVs work so well as vaccine components is straightforward: they present bacterial surface molecules in their native conformation, arranged on a membrane just as the immune system would encounter them during a real infection. This makes for a strong and appropriately targeted immune response. It’s a strategy that researchers are now attempting to extend to other bacterial diseases and even to cancer immunotherapy.

Engineered Vesicles for Drug Delivery and Cancer Treatment

Because BEVs are naturally stable, nano-sized, and capable of being taken up by human cells, they’ve attracted considerable interest as drug delivery vehicles. Researchers have engineered vesicles from E. coli to carry gene-silencing RNA (siRNA) targeted at cancer cells. In one preclinical study, vesicles from a genetically modified E. coli strain were engineered to be roughly eight times less inflammatory than wild-type vesicles, while also displaying a targeting molecule on their surface that directed them specifically to cancer cells overproducing a receptor called HER2. When loaded with siRNA and injected into mice bearing human tumor grafts, these engineered vesicles produced about a two-thirds reduction in tumor growth compared to controls.¹⁶

This kind of work is still in early stages, and no BEV-based drug delivery system has reached clinical use yet. But the concept is being explored for cancer immunotherapy, brain diseases, and bone disease, with both native and engineered vesicles under investigation as nanocarriers.¹⁷ The appeal is that BEVs combine the targeting capabilities of synthetic nanoparticles with the biological complexity of cell-derived structures, carrying natural immune-stimulating molecules alongside whatever therapeutic payload researchers load into them.¹⁸

Diagnostic Potential

BEVs circulate in human body fluids, including blood, urine, and saliva, and their molecular profiles reflect the bacterial communities that produced them. This has led researchers to propose them as a new class of diagnostic biomarker. Because the mix of vesicles in a person’s biofluids changes with disease, comparing the bacterial vesicle composition between patients and healthy individuals could help detect infections, gut disorders, or even cancers associated with microbiome disruption.¹⁹ The concept is compelling, though practical diagnostic tests based on BEV profiling remain in development.²⁰

A significant technical hurdle is purity. Standard methods for isolating vesicles from biological fluids, like filtering by size, tend to co-isolate protein contaminants that aren’t part of the vesicles themselves. In one study examining vesicles from probiotic bacteria, researchers found that size-based purification methods consistently pulled along free proteins, including flagellin, a potent immune activator that would confound any diagnostic reading or therapeutic application. Non-size-based methods like ion-exchange chromatography showed promise for cleaner separation.²¹ Getting the isolation right matters enormously: if you can’t cleanly separate vesicles from the free-floating proteins around them, you can’t be sure whether an observed biological effect comes from the vesicle itself or from a contaminant riding along.

Vesicles in the Ocean

BEVs are not just medically relevant. They play a role in global ecology. Prochlorococcus, the most abundant photosynthetic organism on Earth and a cyanobacterium that dominates tropical and subtropical ocean waters, continuously releases lipid vesicles packed with proteins, DNA, and RNA. Vesicles carrying DNA from diverse bacterial species are abundant in both coastal and open-ocean water samples. Strikingly, Prochlorococcus vesicles can support the growth of other marine bacteria, suggesting they serve as a vehicle for carbon and nutrient transfer in the open ocean.²²

Follow-up work showed that these vesicles contain active enzymes capable of driving biochemical reactions in seawater, and that they readily associate with diverse marine microbes, including Pelagibacter, the most abundant heterotrophic bacterium in the ocean. The emerging picture is that vesicles are not just a cell-to-cell messaging system but a significant player in marine biogeochemistry, potentially mediating energy transfers, catalyzing reactions outside the cell, and even helping microbes cope with reactive oxygen species in sunlit surface waters.²³

Plant-Microbe Interactions

Bacteria use vesicles to interact with plants, too, and the effects cut both ways. Pathogenic bacteria deploy vesicles loaded with toxins and virulence factors to amplify their attack on plant tissues. Beneficial soil microbes, on the other hand, release vesicles that stimulate plant immune defenses and support symbiotic relationships. One particularly intriguing mechanism involves small RNA molecules packed inside vesicles, which can cross into plant cells and modulate immune gene expression, essentially reprogramming the plant’s defenses from the outside.²⁴ This RNA-mediated communication between bacteria and plants via vesicles is part of a growing body of evidence that small RNAs are a universal currency of cross-kingdom signaling.²⁵

An Ancient Feature With Evolutionary Implications

The fact that vesicle secretion is found in bacteria, archaea, and eukaryotes raises a basic evolutionary question: how far back does this behavior go? One provocative hypothesis proposes that the entire internal membrane system of eukaryotic cells, the network of compartments that includes the endoplasmic reticulum, Golgi apparatus, and lysosomes, originated from bacterial outer membrane vesicles. In this model, the mitochondrial ancestor, an ancient bacterium living inside an archaeal host cell, released vesicles into the host’s cytoplasm. Over evolutionary time, those vesicles accumulated and organized into the endomembrane system that defines eukaryotic cell biology today.²⁶ The idea remains a hypothesis, not established fact, but it reframes bacterial vesicles as something potentially foundational to the way complex life organized itself at the cellular level. If correct, every organelle you’ve ever seen in a biology textbook diagram may owe its existence to the same blebbing process that bacteria still use to make vesicles today.